TY - JOUR
T1 - A Pharmacovigilance Study in First Episode of Psychosis :
T2 - Psychopharmacological Interventions and Safety Profiles in the PEPs Project
AU - Bioque, Miquel
AU - Llerena, Adrián
AU - Cabrera, Bibiana
AU - Mezquida, Gisela
AU - Lobo, Antonio
AU - González-Pinto, Ana
AU - Díaz-Caneja, Covadonga M.
AU - Corripio, Iluminada
AU - Aguilar, Eduardo J.
AU - Bulbena Vilarrasa, Antonio
AU - Castro-Fornieles, Josefina
AU - Vieta, Eduard
AU - Lafuente, Amàlia
AU - Mas, Sergi
AU - Parellada, Mara
AU - Saiz-Ruiz, Jerónimo
AU - Cuesta, Manuel J.
AU - Bernardo, Miguel
AU - Gassó, P.
AU - Amoretti, S.
AU - García Bernardo, E.
AU - Tapia-Casellas, C.
AU - Alonso-Solís, Anna
AU - Grasa, Eva
AU - Hernández, M.
AU - González, I.
AU - Ruiz, P.
AU - Modrego, F.
AU - Escartí, M.J.
AU - Mané, Anna
AU - Torrent, C.
AU - Baeza, I.
AU - Contreras, F.
AU - Albacete, Auria
AU - Bobes, Julio
AU - García-Portilla, Maria Paz
AU - Zabala Rabadán, A.
AU - Segarra Echevarría, R.
AU - Rodriguez-Jimenez, R.
AU - Morales-Muñoz, I.
AU - Butjosa, A.
AU - Landin-Romero, R.
AU - Sarró, S.
AU - Ibáñez, Á.
AU - Sánchez-Torres, A.M.
AU - Balanzá-Martínez, Vicent
PY - 2016
Y1 - 2016
N2 - The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P<.001). These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines.
AB - The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P<.001). These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines.
KW - Antipsychotic
KW - First episode psychosis
KW - Pharmacovigilance
KW - Polytherapy
KW - Psychotropic drugs
KW - Schizophrenia
U2 - 10.1093/ijnp/pyv121
DO - 10.1093/ijnp/pyv121
M3 - Article
C2 - 26506856
SN - 1469-5111
VL - 19
JO - International Journal of Neuropsychopharmacology
JF - International Journal of Neuropsychopharmacology
IS - 4
ER -